Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Japanese GPCR medicines specialist Sosei Group today announced that Dr Fiona Marshall has resigned from her position as executive vice president and chief scientific officer of Sosei to assume a senior role outside the company. 19 January 2018
The cost of prescription drugs is at the forefront of discussions among patients, advocacy groups, prescribers, payers, pharmaceutical companies, and policy makers. One factor – though not the only factor – in driving the cost of prescription drugs is the availability of competing products. 19 January 2018
Jordan-headquartered Hikma Pharmaceuticals today announced that Surendera Tyagi will join the company as group chief scientific officer and global head of R&D. 15 January 2018
The Russian government has announced that it will provide subsidies for domestic drugmakers and foreign companies operating in the local market for the partial cover their costs, associated with the forthcoming introduction of labeling procedure in the domestic pharmaceutical market, reports The Pharma Letter’s local correspondent. 13 January 2018
With sales of 97 billion yen ($970 million) for the first half of 2017, a rise of nearly 50% on the previous year, the gastroenterology product Entyvio (vedolizumab) is the best-selling brand of Japanese pharma major Takeda Pharmaceutical. 11 January 2018
Novartis today revealed that Elizabeth (Liz) Barrett, currently global president oncology at Pfizer, will join the company as chief executive of Novartis Oncology and a member of the executive committee of Novartis, effective February 1, 2018 11 January 2018
This year marks the 350th anniversary of German science and technology group Merck KGaA, a milestone that will remind the industry and wider world that it is the oldest operating pharma company in existence anywhere. 10 January 2018
According to US Food and Drug Administration regulations, the regulatory agency may refuse to file a new drug application (NDA) or biologics license application (BLA) when either is deemed incomplete, writes Dr Nicola Davies in her monthly blog for The Pharma Letter. 10 January 2018
French drugmaker Ipsen today announced the promotion of Dr Aidan Murphy as executive vice president, technical operations, effective January 1, 2018. 10 January 2018
Andrew Rut, chief executive of MyMeds&Me, a provider of adverse event and product quality capture software, considers in an Expert View piece how pharma’s ability to run efficient clinical trials is in danger of being compromised by GDPR and a hardening of attitudes on data privacy globally. 9 January 2018
Dr Peter Fellner, who has served as chairman of Belgian biotech firm Ablynx since 2013, has decided to resign from the board with immediate effect. 9 January 2018
US biotech Neurocrine Biosciences has named an experienced Eli Lilly executive its new chief medical officer after Christopher O'Brien announced that he would be retiring. 8 January 2018
Ophthalmic drug specialist Aerie Pharmaceuticals has appointed Julia Williams as director of medical affairs, initially focused on the launch of Rhopressa (netarsudil ophthalmic solution) 0.02%. 3 January 2018
US biotech firm Array BioPharma has launched a new subsidiary to develop drugs using its ARRY-797 drug program, according to a filing with the US Securities and Exchange Commission (SEC). 30 December 2017
US biotech major Amgen has announced its plans to establish the production of its antitumor drug blinatumomab at the facilities of Russian Pharmstandard next year, according to the companies, reports The Pharma Letter’s local correspondent. 26 December 2017
The Russian national Parliament (State Duma) plans to approve a bill that will ease imports of active pharmaceutical ingredients (APIs) to the country, according to press-service of the Russian Duma, reports The Pharma Letter’s local correspondent. 26 December 2017
A decade ago, experts were predicting further integration of contract research organizations (CROs) in clinical trials. And for the most part, they were right. What used to be a vertical, top-down, fixed reporting model industry swiftly shifted to a mixed model utilizing both internal and external resources to conduct clinical trials. 21 December 2017
The Russian government plans to create conditions to increase exports of domestic drugs, which will be effected through the provision of support, both direct and indirect, to local drugmakers and other benefits, including tax and customs, reports The Pharma Letter’s local correspondent. 19 December 2017